Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by hmmmmmmmmon Jan 19, 2023 4:35pm
311 Views
Post# 35234267

baxter numbers

baxter numbersAs wild Baxter numbers are being thrown around- here is what has been disclosed.

Feb. 3, 2020 Baxter initial payment 5 million.

Oct. 28, 2022 Baxter agreed to purchase 2.5m in "7% Convertible Senior Notes" in connection with an amendment to their future milstone payment.

It's hard not to view the Oct 28 money as a life ring to help Spectral get to the 60% trial interim- at which point Baxter can review the trial numbers, and if they wish to continue with the PMX contract- will owe Spectral a modified, smaller milestone payment.

The condition that Spectral would needed to sell $5mil (CDN) in equity units before Baxter would purchase the notes seems to back that up.
(Oct. 28 Securities Purchase Ageement- section 6)
<< Previous
Bullboard Posts
Next >>